Want to see UPB full AI Analyst Report?
Upstream Bio, Inc. (UPB) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Verekitug | Severe Asthma | Phase II | Recruiting | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | May 09, 2025 | ― |
| Verekitug | Chronic Obstructive Pulmonary Disease | Phase II | Recruiting | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | May 09, 2025 | ― |
| Verekitug (Upb-101) | Severe Asthma | Phase II | Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) | Dec 24, 2023 | ― |
| Verekitug (Upb-101) | Chronic Rhinosinusitis With Nasal Polyps | Phase II | Completed | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Dec 01, 2023 | ― |
| Upb-101 | Asthma | Phase I | Completed | Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics | Jun 29, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Verekitug | Phase II | Severe Asthma | Recruiting | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | May 09, 2025 | ― |
| Verekitug | Phase II | Chronic Obstructive Pulmonary Disease | Recruiting | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | May 09, 2025 | ― |
| Verekitug (Upb-101) | Phase II | Severe Asthma | Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) | Dec 24, 2023 | ― |
| Verekitug (Upb-101) | Phase II | Chronic Rhinosinusitis With Nasal Polyps | Completed | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Dec 01, 2023 | ― |
| Upb-101 | Phase I | Asthma | Completed | Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics | Jun 29, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Upstream Bio, Inc. (UPB) have in its pipeline
Upstream Bio, Inc. UPB is currently developing the following drugs: Verekitug, Verekitug (Upb-101), Upb-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.